Data are limited on the potential impact of the injectable progestin contraceptives
(IPC) norethisterone enanthate on risk of vaginal infections. We assessed whether
users of two common IPC (depot medroxyprogesterone acetate [DMPA] and norethisterone
enanthate [NET-EN]) differed in their risk for bacterial vaginosis (BV) and Trichomonas
vaginalis (TV).
To read this article in full you will need to make a payment
Purchase one-time access:
Academic & Personal: 24 hour online accessCorporate R&D Professionals: 24 hour online accessOne-time access price info
- For academic or personal research use, select 'Academic and Personal'
- For corporate R&D use, select 'Corporate R&D Professionals'
Subscribe:
Subscribe to American Journal of Obstetrics & GynecologyAlready a print subscriber? Claim online access
Already an online subscriber? Sign in
Register: Create an account
Institutional Access: Sign in to ScienceDirect
Article Info
Identification
Copyright
© 2015 Published by Elsevier Inc.